Fairfield, Connecticut, United States
IMS Health (NYSE: RX), the world's leading provider of market intelligence to the pharmaceutical and healthcare industries, has announced a comprehensive global program - New Models, New Metrics - to provide the next generation of market measurement services to the pharmaceutical and healthcare industries. The program encompasses a number of IMS initiatives that are transforming the company's core information assets, helping clients make more confident decisions as they address increasingly complex market dynamics.
"The landscape of the pharmaceutical marketplace has changed dramatically in recent years, driven by specialty products, new channels, payer pressures, emerging markets and, especially, generics growth," said Gilles Pajot, executive vice president, IMS. "The implications of these changes for the healthcare and pharmaceutical industries are profound. Only IMS brings a full continuum of information, analytics and consulting capabilities - as well as 'global-to-local' reach - to help clients gain a deep understanding of evolving market dynamics as they shape new business models and strategies."
The first launch under New Models, New Metrics is MIDAS Market Segmentation(TM), a new global standard for measuring and analyzing the generics market segment, and for understanding market opportunities and the performance of products beyond patent expiration. The offering delivers unprecedented visibility to the composition, size and growth of the market based on whether products are "protected" by patents, market exclusivity or other factors. MIDAS Market Segmentation enables pharmaceutical manufacturers to more clearly define the underlying performance of their product portfolios by quickly and consistently characterizing the dynamics of the generics market, as well as the broader market in terms of patent protection status.
With MIDAS Market Segmentation, IMS has categorized generics products into consistent types and reclassified the overall pharmaceutical market, assigning a specific intellectual property protection status to each product, a powerful component to guiding and driving clients' key commercial decisions. By combining this offering with IMS's analytical and consulting capabilities, IMS is better positioned to help clients further improve their forecasting, scenario modeling, competitive benchmarking and portfolio planning activities.
The offering was developed in close collaboration with IMS clients, along with major pharmaceutical and generics industry associations. It is now available in the U.S., Canada, 11 EU countries - Germany, Italy, Spain, France, UK, Belgium, The Netherlands and the Nordic countries - and in South Africa. MIDAS Market Segmentation will be rolled out throughout 2007 to an additional 13 European countries and Japan.
Future offerings under New Models, New Metrics will address emerging markets, parallel trade, specialty channels, disease and treatment patterns, and other evolving market dynamics.
About IMS
Operating in more than 100 countries, IMS Health is the world's leading provider of market intelligence to the pharmaceutical and healthcare industries. With $1.8 billion in 2005 revenue and more than 50 years of industry experience, IMS offers leading-edge business intelligence products and services that are integral to clients' day-to-day operations, including portfolio optimization capabilities; launch and brand management solutions; sales force effectiveness innovations; managed care and over-the-counter offerings; and consulting and services solutions that improve ROI and the delivery of quality healthcare worldwide. Additional information is available at http://www.imshealth.com.
Forward-Looking Statements
This press release includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Although IMS Health believes the expectations contained in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. This information may involve risks and uncertainties that could cause actual results of IMS Health to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to (i) the risks associated with operating on a global basis, including fluctuations in the value of foreign currencies relative to the U.S. dollar, and the ability to successfully hedge such risks, (ii) regulatory, legislative and enforcement initiatives, particularly in the areas of data access and utilization and tax, (iii) to the extent unforeseen cash needs arise, the ability to obtain financing on favorable terms, (iv) to the extent IMS Health seeks growth through acquisitions and joint ventures, the ability to identify, consummate and integrate acquisitions and joint ventures on satisfactory terms, (v) the ability to develop new or advanced technologies and systems for its businesses on time and on a cost-effective basis, and (vi) deterioration in economic conditions, particularly in the pharmaceutical, healthcare or other industries in which IMS Health's customers operate. Additional information on factors that may affect the business and financial results of the Company can be found in the filings of the company made from time to time with the Securities and Exchange Commission.
CONTACT: IMS Communications Clive Savage +44 20 3075 5311 csavage@uk.imshealth.com or Lance Longwell 610-834-5338 llongwell@us.imshealth.com
Source: Business Wire (Business Wire India)